Skip to content
AnalystLens

West Pharmaceutical Services 8-K Report, Financial Results (Oct 29, 2026)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed October 29, 2026
Period End
October 29, 2026
Security
WST
In the record · 2016–202610-K1110-Q338-K118

WST filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Leadership change8-K · Sep ’25Sep ’25

01—Abstract

Summary

Summary of the 8-K filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. reported third-quarter 2026 net sales of $874.5 milliona, up 8.7% from the prior-year period, with organic growth of 11.9%.

Diluted EPS was $3.02b, up 57.3%, and adjusted-diluted EPS was $2.66, up 35.7%. Reported operating profit rose to $267.4 million from $167.6 million, and net income rose to $214.0 million from $140.0 million. Growth was led by the Proprietary Products segment, with net sales of $728.8 million (up 12.6%), and within it High-Value Product (HVP) Components, with net sales of $466.7 million (up 19.7%) and 53% of total company net sales.

West Vantage net sales declined 7.3% to $145.7 millionc, or 6.6% on an organic basis. Management raised full-year 2026 guidance. Net sales are now expected at $3.41 billion to $3.42 billion, up from $3.345 billion to $3.380 billion, with organic net sales growth of 11.3% to 11.6%, up from 10% to 11%.

Adjusted-diluted EPS guidance rose to $9.38 to $9.48d from $8.85 to $9.05. Capital expenditure guidance was lowered to $215 million to $220 million from $250 million to $275 million. The company also reported $685 million of share repurchases year to date, and it declared a fourth-quarter dividend of $0.26 per share, up 18% from $0.22.

The quarter included the completed sale of the SmartDose 3.5mL On-Body Delivery System to AbbVie, which produced a net gain of $55.7 million recorded in other expense (income) and a one-time tax cost of $22.4M associated with that gain. Quarter-to-date SmartDose 3.5mL sales were $11.8 million, and no further sales of the product are expected for the rest of 2026. Year-to-date operating cash flow was $403.4 million and cash and cash equivalents were $464.1 million at September 30, 2026, compared with $791.3 million at December 31, 2025.

02—Key points

Key Highlights

  1. Q3 2026 net sales of $874.5 million, up 8.7% reported and 11.9% organic; Proprietary Products net sales of $728.8 million, up 12.6%.
  2. HVP Components net sales of $466.7 million, up 19.7% and representing 53% of total company net sales; HVP Delivery Devices were flat at $99.1 million.
  3. Diluted EPS of $3.02, up 57.3%; adjusted-diluted EPS of $2.66, up 35.7%; operating profit of $267.4 million versus $167.6 million a year earlier.
  4. Full-year 2026 guidance raised: net sales to $3.41–$3.42 billion, organic growth to 11.3%–11.6%, and adjusted-diluted EPS to $9.38–$9.48.
  5. West Vantage net sales fell 7.3% to $145.7 million (down 6.6% organically), with the filing citing the planned loss of a CGM customer.
  6. Capital expenditure guidance lowered to $215–$220 million from $250–$275 million; $685 million of share repurchases year to date and a Q4 dividend of $0.26 per share, up 18%.
  7. Completed sale of SmartDose 3.5mL to AbbVie, with a $55.7 million net gain recorded in other expense (income); no further SmartDose 3.5mL sales expected in 2026.

03—Questions

Frequently Asked Questions

  1. What drove the strong third-quarter results?

    The filing attributes results mainly to HVP Components within the Proprietary Products segment, where net sales rose 19.7% to $466.7 million. Management cited strong sales performance driving operating income margin expansion and EPS growth. Gross margin was 39.7%, compared with 36.6% in the prior-year quarter.

  2. Why did reported EPS grow faster than adjusted EPS?

    Reported diluted EPS of $3.02 includes a net benefit from M&A activities, primarily the SmartDose 3.5mL sale, which contributed $(0.45) per diluted share of unallocated items in the quarter. Adjusted-diluted EPS of $2.66, up 35.7%, excludes these items as well as restructuring, amortization and other charges.

  3. What changed in full-year guidance?

    Net sales guidance increased to $3.41–$3.42 billion from $3.345–$3.380 billion, organic growth guidance increased to 11.3%–11.6% from 10%–11%, and adjusted-diluted EPS guidance increased to $9.38–$9.48 from $8.85–$9.05. Capital expenditure guidance decreased to $215–$220 million from $250–$275 million.

  4. How is the company returning capital to shareholders?

    The company repurchased $231 million of stock in the third quarter, bringing the year-to-date total to $685 million. Its Board declared a fourth-quarter dividend of $0.26 per share, an increase of 18% over the $0.22 per share paid in the prior quarter.

  5. What is the impact of the SmartDose 3.5mL divestiture?

    The SmartDose 3.5mL On-Body Delivery System and associated facilities were sold to AbbVie. The sale produced a net gain of $55.7 million recorded in other expense (income), offset by a one-time tax cost of $22.4 million. Third-quarter SmartDose 3.5mL net sales were $11.8 million, and the company expects no additional product sales for the remainder of 2026. These sales are excluded from organic growth calculations.

04—Continue

← View all 8-K filings